Business
Therma Bright's Investment Partner Inretio Moves to New Manufacturing Facility
New Space Offers Advanced Development Capabilities for the PREVA (TM) Clot Removal Device for Isc...
About this update from Therma Bright Inc.
[{"type":"text","content":"Therma Bright's Investment Partner Inretio Moves to New Manufacturing FacilityNew Space Offers Advanced Development Capabilities for the PREVA (TM) Clot Removal Device for Ischemic Stroke TreatmentToronto, Ontario--(Newsfile Corp. - March 8, 2023) - Investor partner Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (\"Therma\" or the \"Company\"), developer and investor in a range of leading edge, proprietary diagnostic and medical device technologies, is pleased to provide an update on its partnership with Inretio Inc. (\"Inretio\"), a leading Israeli medical device startup and developer of PREVA™ a novel clot removal device for ischemic stroke treatment. Inretio announced earlier this week it is moving into a new facility of its own in Sapirim Industrial Park, Israel, which is a hub for major technology and medical devices companies in Israel and home for several FDA approved facilities. The new development site will feature a large manufacturing floor and a cleanroom, which will allow the Company to design, develop and manufacture its groundbreaking PREVA™ stroke treatment. The facility spans 10,700 square feet and features state-of-the-art equipment and dedicated spaces specific for research and development, manufacturing, and quality control. In fact, Inretio's new facility is designed to scale production of the PREVA™ device up to 5,000 units per month, whereas the former space had a maximum production capability of 500 units per month. Overall, the new location allows the Company to meet demand for the growing global ischemic stroke treatment market. On average, the current clot retrievers from top competitors sell for between $6200 to $7000 USD per unit. These current competitive ischemic stroke treatment solutions are single use only, much like the PREVA™ device will be a single use solution. \"We are excited to move into our new facility at Sapirim Industrial Park and to have a dedicated space that is tailored to our needs,\" shared Raviv Vine, CEO of Inretio. \"Having our own manufacturing facility is a game-changer for us. It will enable us to produce our PREVA device at scale, which is critical as we move towards clinical trials and potential commercialization.\" \"This expansion into a new space with the right equipment to bring this innovative, leading-edge ischemic stroke solution to mark...